Alnylam wasn't the only biotech company to score on Wall Street after the announcement of its rich RNAi deal with Roche. Isis Pharmaceuticals stands to gain $26.6 million along with milestones and royalties in the deal, and investors bid up its stock price by 17 percent. Isis licensed its RNAi tech to Alnylam in 2004. Report